DOLF Initiating a Follow Up Study on Moxidectin plus Albendazole (MoxA) Combination Treatment for Lymphatic Filariasis and Onchocerciasis in Cote d’Ivoire

DOLF investigators are beginning a follow-up study on the efficacy of a new combination treatment for lymphatic filariasis (LF) and onchocerciasis in the Akoupé district of Côte d’Ivoire. This study began July 4th and builds upon a large-scale community survey sponsored by Medicines Development for Global Health (MDGH). This study aims to determine whether moxidectin […]

DOLF Team’s 2023 in Review

Happy 2024 from the DOLF team! From the field to the lab and back again, here is a brief snap shot of our 2023, a year that saw many new advances and developments in our research on lymphatic filariasis (LF) and onchocerciasis (oncho). As an added bonus, we even learned the best bait for catching […]

DOLF Co-Founder and Co-Director Dr. Gary Weil receives the prestigious Kyelem Prize

We are pleased to share the news that DOLF Co-Director, Gary Weil received the 2023 Kyelem Prize at the annual Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD). Described by some as the “Oscar” of neglected tropical disease (NTD) research, this prize recognizes people in the field who have been particularly effective in bringing […]